{"id":32651,"date":"2017-10-01T11:47:15","date_gmt":"2017-10-01T11:47:15","guid":{"rendered":"http:\/\/i-base.info\/htb\/?p=32651"},"modified":"2017-10-05T14:32:25","modified_gmt":"2017-10-05T14:32:25","slug":"on-demand-dosing-for-prep-is-highly-effective-in-french-expanded-access-programme","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/32651","title":{"rendered":"On-demand dosing for PrEP is highly effective in French expanded access programme"},"content":{"rendered":"<p><strong><img loading=\"lazy\" decoding=\"async\" class=\"alignright size-medium wp-image-32117\" src=\"https:\/\/i-base.info\/htb\/wp-content\/uploads\/2017\/07\/IAS-web-logo1-226x300.png\" alt=\"\" width=\"226\" height=\"300\" srcset=\"https:\/\/i-base.info\/htb\/wp-content\/uploads\/2017\/07\/IAS-web-logo1-226x300.png 226w, https:\/\/i-base.info\/htb\/wp-content\/uploads\/2017\/07\/IAS-web-logo1.png 525w\" sizes=\"auto, (max-width: 226px) 100vw, 226px\" \/>Simon Collins, HIV i-Base<\/strong><\/p>\n<p><strong>Results from the expanded access PrEP programme in France, provided continued efficacy of on-demand or daily dosing for PrEP.<\/strong><\/p>\n<p>This poster, presented by Eric Cua, included data on 2,805 people enrolled from January to December 2016 in an early access programme that covered more than 130 clinics nationally.<\/p>\n<p>This was a high-risk group with 30% having had two or more STIs during the previous year. Approximately 11% had used PEP and 20% used recreational drugs. Median age of participants was 36 years (IQR: 30 to 44) and most (97.4%) were gay men. On-demand dosing was used by 59% of participants.<\/p>\n<p>During 1100 patient years (PY) of follow up, there were four new HIV infections (rate 0.36\/100 PY; CI95%: 0.07 to 7.20). Of these, 2\/4 were acute HIV seroconversions without drug resistance that occurred before inclusion in programme. One case presented with HIV seroconversion at month 1 visit with a 500 copies\/mL and a M184I mutation. The final case presented with seroconversion (with no resistance) two months after PrEP had been stopped (participant decision).<\/p>\n<p>The study notes the high efficacy shown by these data in a real life setting, with the importance of early and continued monitoring given the risk of starting PrEP after recent infection or risk.<\/p>\n<p>Full results from this study were published in the September 2017 edition of Lancet HIV. [2]<\/p>\n<p>References<\/p>\n<ol>\n<li>Molina J-M et al. One-year experience with pre-exposure prophylaxis (PrEP) implementation in France with TDF\/FTC. IAS 2017, 23\u201326 July 2017, Paris. Poster abstract WEPEC0939.<br \/>\n<a href=\"http:\/\/programme.ias2017.org\/Abstract\/Abstract\/3076\">http:\/\/programme.ias2017.org\/Abstract\/Abstract\/3076<\/a><\/li>\n<li>Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study. Lancet HIV: 4(9); e402\u2013e410 (September 2017).<strong><br \/>\n<\/strong><a href=\"http:\/\/dx.doi.org\/10.1016\/S2352-3018(17)30089-9\">dx.doi.org\/10.1016\/S2352-3018(17)30089-9<\/a><\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"<p>Simon Collins, HIV i-Base Results from the expanded access PrEP programme in France, provided continued efficacy of on-demand or daily dosing for PrEP. This poster, presented by Eric Cua, included data on 2,805 people enrolled from January to December 2016 &hellip;<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4,10],"tags":[243],"class_list":["post-32651","post","type-post","status-publish","format-standard","hentry","category-conference-reports","category-transmission-and-prevention","tag-ias-9-paris-2017"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/32651","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=32651"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/32651\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=32651"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=32651"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=32651"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}